Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Lung cancer frequently metastasizes to bone, leading to skeletal-related events (SREs).
• Current treatments like bisphosphonates and denosumab increase the risk of jaw osteonecrosis.
• Statins, HMG-CoA reductase inhibitors, show potential in inhibiting tumor progression and inducing autophagy.

Purpose of the Study:

• To investigate the effect of fluvastatin on lung adenocarcinoma bone metastasis.
• To elucidate the role of autophagy in fluvastatin's anti-metastatic activity.
• To determine the involvement of p53 in fluvastatin-mediated effects.

Main Methods:

• Utilized a nude mouse model of lung adenocarcinoma bone metastasis.
• Administered fluvastatin and assessed its impact on metastasis.
• Investigated the role of autophagy using gene deletion (Atg5, Atg7) and pharmacological inhibitors (3-MA, Baf A1).
• Examined the effect of fluvastatin on nuclear p53 expression.

Main Results:

• Fluvastatin significantly prevented bone metastasis of lung adenocarcinoma in mice.
• The anti-metastatic effect of fluvastatin was dependent on the induction of autophagy in cancer cells.
• Inhibition of autophagy (via gene deletion or inhibitors) abrogated fluvastatin's anti-metastatic effect.
• Fluvastatin increased nuclear p53 expression, and this was crucial for both autophagy induction and anti-metastatic activity.

Conclusions:

• Fluvastatin demonstrates potent anti-bone metastatic properties against lung adenocarcinoma.
• Autophagy induction is a key mechanism mediating fluvastatin's anti-metastatic effects.
• The p53 pathway is essential for fluvastatin-induced autophagy and subsequent suppression of bone metastasis, suggesting a novel therapeutic target.